Regeneron Pharmaceuticals, Inc.
REGN
$735.68
-$6.32-0.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.60B | 13.65B | 13.61B | 13.69B | 13.30B |
| Total Other Revenue | 643.40M | 559.40M | 480.00M | 515.00M | 548.10M |
| Total Revenue | 14.25B | 14.21B | 14.09B | 14.20B | 13.85B |
| Cost of Revenue | 7.72B | 7.48B | 7.21B | 7.10B | 6.82B |
| Gross Profit | 6.53B | 6.73B | 6.87B | 7.10B | 7.03B |
| SG&A Expenses | 2.72B | 2.77B | 2.90B | 2.95B | 2.90B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -10.00M | -- | -- | -- | -500.00K |
| Total Operating Expenses | 10.42B | 10.26B | 10.11B | 10.06B | 9.72B |
| Operating Income | 3.82B | 3.96B | 3.98B | 4.15B | 4.13B |
| Income Before Tax | 5.15B | 4.87B | 4.98B | 4.78B | 4.97B |
| Income Tax Expenses | 567.10M | 416.20M | 484.90M | 367.30M | 314.90M |
| Earnings from Continuing Operations | 4.58K | 4.46K | 4.50K | 4.41K | 4.65K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.58B | 4.46B | 4.50B | 4.41B | 4.65B |
| EBIT | 3.82B | 3.96B | 3.98B | 4.15B | 4.13B |
| EBITDA | 4.35B | 4.47B | 4.47B | 4.63B | 4.60B |
| EPS Basic | 43.44 | 41.75 | 41.76 | 40.88 | 43.23 |
| Normalized Basic EPS | 26.79 | 27.36 | 27.12 | 27.89 | 27.48 |
| EPS Diluted | 41.77 | 39.69 | 39.29 | 38.29 | 40.41 |
| Normalized Diluted EPS | 25.72 | 25.98 | 25.52 | 26.14 | 25.69 |
| Average Basic Shares Outstanding | 423.00M | 427.50M | 430.50M | 431.60M | 430.60M |
| Average Diluted Shares Outstanding | 440.80M | 449.80M | 456.60M | 460.50M | 460.50M |
| Dividend Per Share | 2.64 | 1.76 | 0.88 | -- | -- |
| Payout Ratio | 6.06% | 4.18% | 2.08% | -- | -- |